Clinical research company Medpace Holdings (NASDAQ: MEDP) will be reporting earnings this Wednesday after market hours. Here’s what investors should know.

Medpace beat analysts’ revenue expectations last quarter, reporting revenues of $706.6 million, up 26.5% year on year. It was a satisfactory quarter for the company, with a beat of analysts’ EPS estimates but full-year EPS guidance in line with analysts’ estimates.

Is Medpace a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Medpace’s revenue to grow 14.3% year on year, in line with the 14.2% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Medpace has missed Wall Street’s revenue estimates multiple times over the last two years.

With Medpace being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unfold for life sciences tools & services stocks. However, there has been positive investor sentiment in the segment, with share prices up 9.9% on average over the last month. Medpace is up 15.8% during the same time .

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.